Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03277196
Recruitment Status : Recruiting
First Posted : September 8, 2017
Last Update Posted : April 23, 2019
Sponsor:
Information provided by (Responsible Party):
Vertex Pharmaceuticals Incorporated

Brief Summary:
This is a Phase 3, 2-arm, multicenter study with an open-label ivacaftor arm and an observational arm to evaluate the safety and efficacy of long-term ivacaftor treatment in subjects with cystic fibrosis (CF) who are <24 months of age at treatment initiation and have an approved Ivacaftor-Responsive mutation

Condition or disease Intervention/treatment Phase
Cystic Fibrosis Drug: Ivacaftor Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 75 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3, 2-Arm, Open-label Study to Evaluate the Safety and Pharmacodynamics of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation
Actual Study Start Date : August 16, 2017
Estimated Primary Completion Date : June 7, 2021
Estimated Study Completion Date : June 7, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cystic Fibrosis
Drug Information available for: Ivacaftor

Arm Intervention/treatment
Experimental: Ivacaftor Arm Drug: Ivacaftor
Ivacaftor will be administered every 12 hours (q12h) from Day 1 through the morning dose of the Week 96 Visit.
Other Name: VX-770

No Intervention: Observational Arm



Primary Outcome Measures :
  1. Safety assessments based on the number of subjects with adverse events (AEs) and serious adverse events (SAEs) [ Time Frame: from baseline through safety follow-up (up to 24 weeks after last dose) ]
    Number of subjects with AEs and SAEs will be reported.


Secondary Outcome Measures :
  1. Absolute change in sweat chloride [ Time Frame: from baseline through Week 96 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 24 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Ivacaftor Arm: Subjects From Study 124 (NCT02725567 ) Part B:

  • Subjects transitioning from Study 124 Part B must have completed the last study visit of Study 124 Part B.
  • As judged by the investigator, parent or legal guardian must be able to understand protocol requirements, restrictions, and instructions; and must sign the informed consent form (ICF).

Ivacaftor Arm: Subjects Not From Study 124 Part B:

  • Confirmed diagnosis of CF, or 2 CF-causing mutations.
  • An ivacaftor- responsive CFTR mutation on at least 1 allele. Subjects will be eligible in countries/regions where ivacaftor is approved for use in subjects 2 years of age and older.
  • As judged by the investigator, parent or legal guardian must be able to understand protocol requirements, restrictions, and instructions; and must sign the ICF.

Observational Arm:

  • Received ivacaftor treatment in Study 124 Part B and elected not to enroll or ineligible to enroll in the ivacaftor arm of Study 126.

Exclusion Criteria:

Ivacaftor Arm: Subjects From Study 124 Part B:

  • History of any illness or condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering ivacaftor to the subject.
  • Subjects receiving commercially available ivacaftor treatment

Ivacaftor Arm: Subjects Not From Study 124 Part B:

  • History of any illness or condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering ivacaftor to the subject
  • An acute upper or lower respiratory infection, or pulmonary exacerbation, or changes in therapy for pulmonary disease within 4 weeks of Day 1
  • Abnormal liver function at screening
  • Hemoglobin <9.5 g/dL at screening
  • History of solid organ or hematological transplantation
  • Use of any moderate or strong inducers or inhibitors of CYP3A within 2 weeks of Day 1

Observational Arm:

  • Receiving ivacaftor treatment

Other protocol defined Inclusion/Exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03277196


Contacts
Layout table for location contacts
Contact: Medical Information 617-341-6777 medicalinfo@vrtx.com

  Hide Study Locations
Locations
Layout table for location information
United States, Alabama
University of Alabama at Birmingham Recruiting
Birmingham, Alabama, United States, 35233
United States, California
Stanford University Recruiting
Palo Alto, California, United States, 94034
United States, Delaware
Alfred I DuPont Hospital for Children Recruiting
Wilmington, Delaware, United States, 19803
United States, Florida
Nemours Children's Hospital Recruiting
Orlando, Florida, United States, 32827
United States, Georgia
Center for Advanced Pediatrics Recruiting
Atlanta, Georgia, United States, 30329
United States, Illinois
Ann & Robert Lurie Children's Hospital of Chicago Recruiting
Chicago, Illinois, United States, 60611
United States, Indiana
Riley Hospital for Children at Indiana University Health Recruiting
Indianapolis, Indiana, United States, 46202
United States, Maryland
John Hopkins Hospital Recruiting
Baltimore, Maryland, United States, 21287
United States, Massachusetts
Boston Children's Hospital Recruiting
Boston, Massachusetts, United States, 02115
United States, Minnesota
Childrens's Hospitals and Clinics of Minnnesota Recruiting
Minneapolis, Minnesota, United States, 55404
United States, Missouri
Children's Mercy Hospital Recruiting
Kansas City, Missouri, United States, 64108
United States, Montana
Billings Clinic Hospital Recruiting
Billings, Montana, United States, 59101
United States, Ohio
Nationwide Children's Hospital Recruiting
Columbus, Ohio, United States, 43205
United States, Pennsylvania
Children's Hospital of Philadelphia Recruiting
Philadelphia, Pennsylvania, United States, 19104
United States, Texas
Texas Children's Hospital Recruiting
Houston, Texas, United States, 77030
United States, Washington
Seattle Children's Hospital Recruiting
Seattle, Washington, United States, 98105
United States, Wisconsin
University of Wisconsin Recruiting
Madison, Wisconsin, United States, 53792
Australia
Lady Cilento Children's Hospital Recruiting
South Brisbane, Australia
Canada, Ontario
The Hospital for Sick Children Recruiting
Toronto, Ontario, Canada
Germany
Universitaetsklinikum Heidelberg, Zenter fuer Kinder-und Jugendmedizin Recruiting
Heidelberg, Germany
Ireland
Children's University Hospital Temple Street Recruiting
Dublin, Ireland
Our Lady's Children's Hospital Recruiting
Dublin, Ireland
University Hospital Limerick Recruiting
Limerick, Ireland
United Kingdom
Royal Hospital for Sick Children Recruiting
Edinburgh, United Kingdom
Alder Hey Children's Alder Hey Children's NHS Foundation Trust Recruiting
Liverpool, United Kingdom
Great Ormond Street Hospital for Sick Children Recruiting
London, United Kingdom
Royal Brompton & Harefield NHS Founcation Trust, Royal BromptonHospital Recruiting
London, United Kingdom
Royal Manchester Children's Hospital Recruiting
Manchester, United Kingdom
Oxford University Hospitals NHS Trust, John Radcliffe Hospital Recruiting
Oxford, United Kingdom
Sponsors and Collaborators
Vertex Pharmaceuticals Incorporated

Layout table for additonal information
Responsible Party: Vertex Pharmaceuticals Incorporated
ClinicalTrials.gov Identifier: NCT03277196     History of Changes
Other Study ID Numbers: VX15-770-126
2017-001379-21 ( EudraCT Number )
First Posted: September 8, 2017    Key Record Dates
Last Update Posted: April 23, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cystic Fibrosis
Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Ivacaftor
Chloride Channel Agonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action